DURECT strikes deal with Impax to get Eladur back into development

Impax Labs (IPXL -1.7%) and DURECT (DRRX +5.6%) announce a development and commercialization agreement for the PHN patch, Eladur.

IPXL is paying $2M upfront for exclusive worldwide rights.

Additional payments could reach $61M depending upon "the achievement of predefined development and commercialization milestones."

DRRX also gets royalties assuming the patch reaches the market.

IPXL is controlling and funding development. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs